Xeomin

Xeomin is a Merz Aesthetics botulinum toxin type A brand with the nonproprietary name incobotulinumtoxinA. Xeomin is often discussed when readers compare formulation, storage, and unit language across major type A products.

Shared serotype does not make Xeomin clinically interchangeable with Botox, Dysport, Jeuveau, Daxxify, Letybo, or other toxin brands. Its interpretation depends on Xeomin’s own label, evidence base, formulation, and market.

Who Makes Xeomin?

Merz Pharmaceuticals GmbH manufactures Xeomin, according to the current Xeomin prescribing information on DailyMed 🔗. Readers may encounter Merz Therapeutics in clinical contexts, while Merz Aesthetics represents the aesthetic business behind Xeomin.

Product Identity

Field	Reference point
Brand	Xeomin
Nonproprietary name	IncobotulinumtoxinA
Toxin type	Botulinum toxin type A

Merz Roles Around Xeomin

Entity	Role
Merz Pharmaceuticals GmbH	Manufacturer identified in the U.S. prescribing information and applicant named in FDA approval letters 🔗.
Merz Pharmaceuticals, LLC	U.S. labeler and packager identified in the current DailyMed record 🔗.
Merz Aesthetics	Leads Xeomin’s medical-aesthetics portfolio, clinical development, regulatory, and commercial context (Merz Aesthetics business overview 🔗).
Merz Therapeutics	Leads neurological indication development, therapeutic product context, and related market partnerships (Merz Therapeutics business overview 🔗).

Formulation Context

Xeomin is frequently described through incobotulinumtoxinA formulation language. The current Xeomin label 🔗 describes a 150 kDa active neurotoxin without accessory proteins, while the current Botox Cosmetic label 🔗 describes a neurotoxin complex that includes accessory proteins. Xeomin is not additive-free or protein-free: each vial also contains human albumin and sucrose.

The absence of accessory proteins is a formulation distinction. On its own, it does not establish superior efficacy, safety, or duration, or a lower rate of neutralizing-antibody formation or secondary clinical nonresponse than Botox or another product.

Jürgen Frevert, Ph.D. connects the NT201 development program with Merz’s product-science history. His company-affiliated 2009 Xeomin paper 🔗 helps document how the product was developed and described; it does not independently establish clinical superiority over another toxin product.

Misleading Purity and Resistance Claims

There is no universal regulatory definition or clinical ranking that makes one botulinum toxin product “purer,” “cleaner,” or the “cleanest.” Xeomin is also not a Botox brand: Xeomin is the brand name for incobotulinumtoxinA, while Botox and Botox Cosmetic are brands for onabotulinumtoxinA.

Two clinic comparisons illustrate how this distinction is often overstated. A Bowtique Med Spa comparison 🔗 describes Xeomin as having “no added proteins” and infers a lower risk of resistance, while a Cosmetic Skin & Laser Center comparison 🔗 calls it additive-free and the “purest injectable available.” Human albumin is a protein listed among Xeomin’s inactive ingredients, so “without accessory proteins” is the accurate formulation distinction. The presence or absence of accessory proteins also does not by itself establish a comparative rate of antibody-related clinical nonresponse: Merz Aesthetics states that head-to-head studies 🔗 evaluating relative immunogenicity risk on that basis have not been performed.

Label Context

In the United States, Xeomin’s incobotulinumtoxinA prescribing information covers both therapeutic and aesthetic indications. The June 2026 FDA prescribing information 🔗 defines the following approved uses and populations.

Label context	Approved indication	Population
Therapeutic	Chronic sialorrhea	Patients 2 years of age and older
Therapeutic	Upper limb spasticity	Patients 2 years of age and older, including pediatric patients with spasticity associated with cerebral palsy
Therapeutic	Cervical dystonia	Adults
Therapeutic	Blepharospasm	Adults
Aesthetic	Temporary improvement of moderate to severe upper facial lines: glabellar lines, horizontal forehead lines, and lateral canthal lines / crow’s feet	Adults

FDA approved the upper facial lines expansion on July 5, 2024, covering glabellar lines, horizontal forehead lines, and lateral canthal lines in adults, treated individually or simultaneously within the label (FDA supplement approval letter 🔗). This milestone also appears in the U.S. FDA approval timeline.

The label retains a boxed warning about distant spread of toxin effect, and Xeomin units cannot be compared with or converted into the units of another botulinum toxin product.

Xeomin is not universally cheaper. Patient price, vial price, professional fees, market, and treatment area can all affect cost. Both the Xeomin label 🔗 and Botox Cosmetic label 🔗 specify 20 of their own product-specific units for labeled glabellar-line treatment, but the matching number does not make those units interchangeable. Unit count alone cannot establish a universal price or cost-effectiveness advantage; see How Botulinum Toxin Units Should Be Interpreted.

Uses not listed in the current prescribing information should not be presented as FDA-approved Xeomin indications.

Regional labels may differ. A product name, toxin type, or company statement should not replace local prescribing information.

Recent Regulatory and Market Updates

Date	Market	Development
July 1, 2026	Brazil	Grünenthal assumed responsibility for Xeomin commercialization from Biolab Farmacêutica under an expanded partnership with Merz Therapeutics. This was a commercial-role change, not a new indication (Merz Therapeutics announcement 🔗).
June 26, 2026	United States	The FDA-approved label update expanded the pediatric upper limb spasticity indication to include patients aged 2 years and older with spasticity associated with cerebral palsy (Merz Therapeutics announcement 🔗; FDA prescribing information 🔗).
June 19, 2026	Japan	Japan’s Ministry of Health, Labour and Welfare approved cervical dystonia and blepharospasm as additional Xeomin indications. They became the product’s fourth and fifth approved indications in Japan (Teijin and Merz Therapeutics announcement 🔗).
January 26, 2026	European Union and EEA	Merz Therapeutics submitted a regulatory application for lower- and upper-limb spasticity in children and adolescents aged 2–17 years. The announcement describes a submission, not an approval (Merz Therapeutics announcement 🔗).